Format

Send to

Choose Destination
JCI Insight. 2017 May 4;2(9). pii: 93474. doi: 10.1172/jci.insight.93474. eCollection 2017 May 4.

18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response.

Author information

1
Laboratory for Translational and Molecular Imaging, Cancer and Stem Cell Biology Programme, and.
2
Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore.
3
Department of Infectious Diseases, Singapore General Hospital, Singapore.
4
Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore.
5
Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland.

Abstract

Development of antiviral therapy against acute viral diseases, such as dengue virus (DENV), suffers from the narrow window of viral load detection in serum during onset and clearance of infection and fever. We explored a biomarker approach using 18F-fluorodeoxyglucose (18F-FDG) PET in established mouse models for primary and antibody-dependent enhancement infection with DENV. 18F-FDG uptake was most prominent in the intestines and correlated with increased virus load and proinflammatory cytokines. Furthermore, a significant temporal trend in 18F-FDG uptake was seen in intestines and selected tissues over the time course of infection. Notably, 18F-FDG uptake and visualization by PET robustly differentiated treatment-naive groups from drug-treated groups as well as nonlethal from lethal infections with a clinical strain of DENV2. Thus, 18F-FDG may serve as a novel DENV infection-associated inflammation biomarker for assessing treatment response during therapeutic intervention trials.

KEYWORDS:

Infectious disease; Inflammation

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center